全文获取类型
收费全文 | 26538篇 |
免费 | 1854篇 |
国内免费 | 193篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 1513篇 |
妇产科学 | 654篇 |
基础医学 | 2240篇 |
口腔科学 | 115篇 |
临床医学 | 2574篇 |
内科学 | 7918篇 |
皮肤病学 | 463篇 |
神经病学 | 2006篇 |
特种医学 | 254篇 |
外科学 | 3007篇 |
综合类 | 703篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2236篇 |
眼科学 | 954篇 |
药学 | 1134篇 |
2篇 | |
中国医学 | 64篇 |
肿瘤学 | 2647篇 |
出版年
2024年 | 41篇 |
2023年 | 254篇 |
2022年 | 244篇 |
2021年 | 359篇 |
2020年 | 349篇 |
2019年 | 122篇 |
2018年 | 473篇 |
2017年 | 501篇 |
2016年 | 564篇 |
2015年 | 549篇 |
2014年 | 472篇 |
2013年 | 727篇 |
2012年 | 2022篇 |
2011年 | 2331篇 |
2010年 | 867篇 |
2009年 | 812篇 |
2008年 | 2478篇 |
2007年 | 2359篇 |
2006年 | 2034篇 |
2005年 | 2124篇 |
2004年 | 2109篇 |
2003年 | 2148篇 |
2002年 | 1732篇 |
2001年 | 1297篇 |
2000年 | 311篇 |
1999年 | 173篇 |
1998年 | 231篇 |
1997年 | 135篇 |
1996年 | 112篇 |
1995年 | 67篇 |
1994年 | 82篇 |
1993年 | 47篇 |
1992年 | 48篇 |
1991年 | 40篇 |
1990年 | 42篇 |
1989年 | 44篇 |
1988年 | 41篇 |
1987年 | 40篇 |
1986年 | 35篇 |
1985年 | 32篇 |
1984年 | 26篇 |
1983年 | 12篇 |
1982年 | 19篇 |
1981年 | 20篇 |
1980年 | 12篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
91.
92.
93.
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure 总被引:9,自引:0,他引:9
Yancy CW Fowler MB Colucci WS Gilbert EM Bristow MR Cohn JN Lukas MA Young ST Packer M;U.S. Carvedilol Heart Failure Study Group 《The New England journal of medicine》2001,344(18):1358-1365
BACKGROUND: The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure. METHODS: In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients. RESULTS: As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared with nonblack patients were 0.74 (95 percent confidence interval, 0.42 to 1.34) and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. Carvedilol also improved functional class, ejection fraction, and the patients' and physicians' global assessments in both the black patients and the nonblack patients. For all these measures of outcome and clinical status, carvedilol was superior to placebo within each racial cohort (P<0.05 in all analyses), and there was no significant interaction between race and treatment (P> 0.05 in all analyses). CONCLUSIONS: The benefit of carvedilol was apparent and of similar magnitude in both black and nonblack patients with heart failure. 相似文献
94.
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations
95.
van Leth F Huisamen CB Badaro R Vandercam B de Wet J Montaner JS Hall DB Wit FW Lange JM;NN Study Group 《Journal of acquired immune deficiency syndromes (1999)》2005,38(3):296-300
BACKGROUND: The initial rate of plasma HIV-1 RNA (pVL) decline has been proposed as a marker of early efficacy of antiretroviral therapy (ART) and a possible predictor of late efficacy. We compared the rate of pVL decline in patients starting ART with nevirapine (NVP), efavirenz (EFV), or both drugs combined in addition to lamivudine (3TC) and stavudine (d4T). METHODS: Analysis of the viral decay constant (VDc) during the first 2 weeks of treatment in patients enrolled in the 2NN study who remained on allocated treatment. RESULTS: The median VDc (log10 copies per day, [interquartile range]) was similar for NVP (0.30 [0.25-0.36], EFV (0.31 [0.27-0.37]), and NVP + EFV (0.30 [0.27-0.36]). Patients with a baseline pVL >100,000 copies/mL were 8.7 (95% confidence interval [CI]: 6.2-12.3) times more likely to have a VDc >75th percentile. A high VDc was not associated with plasma drug concentration or with a decreased risk of virologic failure at week 48 after the start of therapy (hazard ratio = 0.8, 95% CI: 0.6-1.2). CONCLUSION: NVP, EFV, or NVP + EFV in combination with 3TC and d4T show similar rates of pVL decline during the first 2 weeks of treatment. The VDc with these regimens is not predictive of late virologic efficacy. 相似文献
96.
Balotta C Facchi G Violin M Van Dooren S Cozzi-Lepri A Forbici F Bertoli A Riva C Senese D Caramello P Carnevale G Rizzardini G Cremonini L Monno L Rezza G Perno CF Ippolito G d'Arminio-Monforte A Vandamme AM Moroni M;ICONA Study Group 《Journal of acquired immune deficiency syndromes (1999)》2001,27(5):499-505
97.
Guidelines for the validation and application of typing methods for use in bacterial epidemiology 总被引:3,自引:0,他引:3
A. van Belkum P. T. Tassios L. Dijkshoorn S. Haeggman B. Cookson N. K. Fry V. Fussing J. Green E. Feil P. Gerner-Smidt S. Brisse M. Struelens for the European Society of Clinical Microbiology Infectious Diseases Study Group on Epidemiological Markers 《Clinical microbiology and infection》2007,13(S3):1-46
98.
A. Stathi J. Papaparaskevas L. Zachariadou A. Pangalis N. J. Legakis A. Tseleni-Kotsovili the Hellenic Strep-EURO Study Group P. T. Tassios 《Clinical microbiology and infection》2008,14(8):808-812
Among a total of 101 isolates from the first systematic multicentre surveillance effort concerning invasive Streptococcus pyogenes disease in Greece, conducted between 2003 and 2005 and covering 38% of the population, emm types 1 and 12 were prevalent, being responsible for 27 and nine cases, respectively. The isolates from the remaining 65 cases were assigned to 26 other emm types. Erythromycin resistance (12 isolates) was primarily mef (A)-mediated, although all emm type 1 strains were susceptible. Tetracycline resistance, due mostly to tet (M), was detected in 26 isolates. Subtyping by pulsed-field gel electrophoresis yielded 50 chromosomal fingerprints, thus discriminating further among ten of the 28 observed emm types. 相似文献
99.
Coppin H Ribouchon MT Bausero P Pessac B Fontaine B Semana G Clanet M Roth MP;French Multiple Sclerosis Genetics Group 《Genes and immunity》2000,1(8):478-482
The myelin basic protein (MBP) gene is a candidate locus for susceptibility to multiple sclerosis. Several groups have tested a complex (TGGA)n repeat in the 5' region of this gene for association/linkage with multiple sclerosis, with divergent results. This region of tandem repetitive sequence has been subjected to complex rearrangements, and there is a possibility that alleles of the same size have different internal structures, which reduces the interest of this marker for linkage disequilibrium studies and may at least partly explain the conflicting results obtained so far. To overcome this problem, we isolated a new polymorphic (CA)n repeat within the Golli-MBP locus. The limited number of alleles identified makes this other marker suitable for transmission disequilibrium studies. We tested this marker for linkage with multiple sclerosis, using the transmission-disequilibrium test (TDT) on a sample of 196 nuclear families in which the genotypes of both parents could be unambiguously defined. We found no evidence of transmission disequilibrium between multiple sclerosis and any of the three alleles of this marker, even when the patients were subdivided according to their HLA-DRB1*1501 status. The present data thus provide no evidence for a contribution of the MBP gene to multiple sclerosis susceptibility in French patients. 相似文献
100.
Gompels MM Hodges E Lock RJ Angus B White H Larkin A Chapel HM Spickett GP Misbah SA Smith JL;Associated Study Group 《Clinical and experimental immunology》2003,134(2):314-320
We have undertaken a retrospective study of antibody deficient patients, with and without lymphoma, and assessed the ability of specific polymerase chain reaction (PCR) primers to determine if the detection of clonal lymphocyte populations correlates with clinical and immunohistochemical diagnosis of lymphoma. We identified 158 cases with antibody deficiency presenting during the past 20 years. Paraffin-embedded biopsy specimens or slides were available for analysis in a cohort of 34 patients. Of these patients, 29 had common variable immunodeficiency, one X-linked agammaglobulinaemia, one X-linked immunoglobulin deficiency of uncertain cause and three isolated IgG subclass deficiency. We have confirmed that lymphoma in antibody deficiency is predominantly B cell in origin. Clonal lymphocyte populations were demonstrated in biopsies irrespective of histology (16/19 with lymphoma and 11/15 without). Isolated evidence of clonality in biopsy material is therefore an insufficient diagnostic criterion to determine malignancy. Furthermore, our data suggest that clonal expansions are rarely the result of Epstein-Barr virus-driven disease. 相似文献